Abstract

PurposeTo evaluate the dosimetry and acute toxicity of helical tomotherapy for locoregional irradiation of patients after breast-conserving surgery. Patients and methodsTwenty breast cancer patients with breast-conserving surgery treated by helical tomotherapy have been studied. The median age was 49 (min: 25, max: 69). The whole breast, tumour bed and lymph nodes were prescribed 52.2Gy, 63.8Gy and 50.4Gy, all in 29 fractions. The dose per fraction was 2.2Gy to the boost, 1.8Gy to the breast and 1.74Gy to the lymph node volumes. The reproducibility was analysed by recording the daily shifts in x, y and z directions and roll rotation. All toxicities were described using the Common Terminology Criteria for Adverse Effects v3.0. ResultsTwenty-two tumours were irradiated. Six-eight percent were located in the inner quadrant. In 90 % of patients supraclavicular and internal mammary nodes were treated. The coverage of planning target volumes (PTV) was as follows: PTV boost: V107=0.3 %±0.5 SD, V95=98.4 %±1.9 SD; PTV breast: −V107=7.8 %±17.3 SD, V95=96.8 %±2.2 SD; PTV LN: V107=2.5 %±4.2 SD, V95=92.7 %±13.2 SD. The mean V20 of the homolateral lung was 18.9 %±3.5 SD. For left side lesion, the mean V30 of the heart was 0.9 %±0.8 SD. The mean V5 was: V5 homolateral lung: 73.1 %±11.8 ET, controlateral lung: 38.9 %±21, heart (left side breast): 57.3 %±21, controlateral breast: 15.5 %±9.6. Median shifts were as follow: x-axis –0.04mm (IC 95: –0.4 +0.38), y-axis –0.37mm±5.51 (IC 95: –0.88 +0.14), z-axis 2.90mm±5.42 (IC 95:+2.4+3.4) and roll rotation 0.22±1.10 (IC 95: –0.1+0.32). The treatment tolerance was acceptable with 1 definitive interruption couple of fractions before the end and 3 temporal interruptions for skin toxicity. No grade 3 or 4 toxicity. Ninety-five percent of patients experienced skin toxicity: 45 % grade 2. There were 3 cases of oesophagitis. The median follow-up of presented series is 9.7 months and all of the patients are free of disease without any residual early or late toxicity. ConclusionsHelical tomotherapy can achieve full target coverage while protected to the heart and ipsilateral lung. This treatment was well tolerated and reproducible. However, the low doses to normal tissue volumes need to be reduced in future studies.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.